How can research be conducted responsibly and in a way that minimizes the potential for further exacerbating the problem of antibiotic resistance?

Sep 7, 2000 ... We conducted an epidemiologic and molecular investigation of endemic P. aeruginosa infection among infants in a neonatal intensive care unit. May 23, 2023 ... Carbapenem Resistant Pseudomonas aeruginosa (CRPA) · P. aeruginosa causes an estimated 51,000 health care-associated infections in the U.S. ... Jul 5, 2018 ... aeruginosa. For many people, a Pseudomonas infection will only cause mild symptoms. However, if a person is in a hospital or has a weakened ... aeruginosa eradication rate of 40% (95% CI 34–45%; p<0.00001), with no significant heterogeneity (I2=0%). Combined systemic and inhaled antibiotic treatment was ... Antibiotics with a novel mode of action will be needed to avoid cross resistance against currently used therapeutic agents. Importantly, antivirulence drugs are ... Objective. Investigate clonal dissemination of nosocomial multidrug-resistant Pseudomonas aeruginosa isolates within and between Brazilian intensive care ... Pseudomonas aeruginosa are strains of bacteria that are widely found in the environment. Pseudomonas is a major cause of lung infections in people with ... Pseudomonas aeruginosa (P. aeruginosa) is the most common Gram-negative rod infection, especially in severely sick and vulnerable individuals. Treatment ... Jun 25, 2022 ... Pseudomonas aeruginosa is a multi-drug resistance (MDR) opportunistic pathogens, causing acute or chronic infection in immunocompromised individuals. Nov 29, 2023 ... Agent Characteristics Risk Group: RG-2 associated with human disease, rarely serious; preventive or therapeutic interventions often available.